Disease Domain | Count |
---|---|
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Synthetic peptide | 1 |
Top 5 Target | Count |
---|---|
PTH1R(Parathyroid hormone receptor) | 1 |
AR(Androgen Receptor) | 1 |
ERα(Estrogen receptor alpha) | 1 |
Target |
Mechanism ERα antagonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date27 Jan 2023 |
Target |
Mechanism PTH1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Apr 2017 |
Target- |
Mechanism Osteoclasts inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Italy |
First Approval Date01 Jan 1993 |
Start Date01 Jun 2024 |
Sponsor / Collaborator [+1] |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
Start Date13 Apr 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Abaloparatide ( PTH1R ) | Osteoporosis, Postmenopausal More | Approved |
Alendronate Sodium | Osteoporosis, Postmenopausal More | Approved |
RAD-140 ( AR ) | Breast Cancer More | Phase 1 |
Elacestrant hydrochloride ( ERα ) | Vasomotor symptom More | Discontinued |
Cannabidiol | Prader-Willi Syndrome More | Discontinued |